

DAFTAR PUSTAKA

1. Del Barrio V. Diagnostic and statistical manual of mental disorders. 5th ed. The Curated Reference Collection in Neuroscience and Biobehavioral Psychology. Washington DC; 2016.
2. Kendrick T, Pilling S. Common mental health disorders - Identification and pathways to care: NICE clinical guideline. Vol. 62, British Journal of General Practice. Leicester (UK): British Psychological Society; 2012.47–49 p.
3. Kementerian Kesehatan Republik Indonesia. Laporan Nasional Riskesdas 2018 [Internet]. Jakarta: Balitbang Kemenkes RI; 2018. [Diakses 2020 Okt 2]. Tersedia dari: [http://www.yankes.kemkes.go.id/assets/downloads/PMK No. 57 Tahun 2013 tentang PTRM.pdf](http://www.yankes.kemkes.go.id/assets/downloads/PMK%20No.%2057%20Tahun%202013%20tentang%20PTRM.pdf)
4. Albert D, Block AM, Bruce BB, Haines DE, McCloskey LJ, Mitchell RN et al. Dorland's Illustrated Medical Dictionary. 32nd ed. Philadelphia: Elsevier; 2012.109 p.
5. Miller BF, Keane CB. Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health. 7th ed. Vol. 15, Gastroenterology Nursing. London: Elsevier; 2003.
6. D'Souza R, Hooten WM. Extrapiramidal symptoms [Internet]. StatPearls Publishing. Treasure Island (FL): StatPearls Publishing; 2020 [Diakses 2020 Okt 2]. Tersedia dari: <https://www.ncbi.nlm.nih.gov/books/NBK534115/>
7. Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2006;7(6):268–74.
8. Yulianty MD, Cahaya N, Srikartika VM. Studi Penggunaan Antipsikotik dan Efek Samping pada Pasien Skizofrenia di Rumah Sakit Jiwa Sumbang Lihum Kalimantan Selatan. J Sains Farm Klin. 2017;3(2):153.
9. Hasni D, Ridho M, Anissa M. Gambaran Sindrom Ekstrapiramidal Pada Pasien Skizofrenia Yang Mendapat Terapi Antipsikotik. J Kedokt Yars. 2020;27(3):090–4.
10. Dania H, Faridah IN, Rahmah KF, Abdulah R, Barliana MI, Perwitasari DA. Hubungan Pemberian Terapi Antipsikotik terhadap Kejadian Efek Samping Sindrom Ekstrapiramidal pada Pasien Rawat Jalan di Salah Satu Rumah Sakit di Bantul, Yogyakarta. Indones J Clin Pharm. 2019;8(1):19–31.
11. Rukmana S. Kajian penggunaan obat antipsikotik terhadap pasien skizofrenia di rawat inap Rumah Sakit Jiwa H.B Saanin Padang [Skripsi]. Padang: Fakultas Kedokteran Universitas Andalas; 2017. <http://scholar.unand.ac.id/22301/>
12. Antipsikotik atipikal [Internet]. BPOM RI. [Diakses 2020 Okt 3]. Tersedia dari: <http://pionas.pom.go.id/ioni/bab-4-sistem-saraf-pusat/42-psikosis-dan-gangguan-sejenis/421-antipsikosis/antipsikotik>
13. Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014.
14. World Health Organization. The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization. Geneva: World Health Organization;

- 2016.
15. Castle D, Morgan V. Epidemiology. In: Mueser K, Jeste D, editors. *Clinical Handbook of Schizophrenia*. 1st ed. The Guildford Press; 2008. p. 14–24.
 16. Simeone JC, Ward AJ, Rotella P, Collins J, Windisch R. An evaluation of variation in published estimates of schizophrenia prevalence from 1990–2013: A systematic literature review. *BMC Psychiatry*. 2015;15(1):193.
 17. Grignon S, Trottier M. Capgras syndrome in the modern era: Self misidentification on an ID picture [2]. *Can J Psychiatry*. 2005;50(1):74–5.
 18. Siever LJ, Davis KL. The Pathophysiology of Schizophrenia Disorders: Perspectives from the Spectrum. *Am J Psychiatry*. 2004;161(3):398–413.
 19. Crismon L, Argo T, Buckley P. Schizophrenia. In: DiPiro J, Talbert R, Yee G, Al E, editors. *Pharmacotherapy: A Pathophysiologic Approach*. 9th ed. New York: McGraw-Hill; 2014. p. 1019–46.
 20. McDonald C, Murphy KC. The new genetics of schizophrenia. *Psychiatr Clin North Am*. 2003;26(1):41–63.
 21. Crow TJ. Obstetric complications and schizophrenia. *Am J Psychiatry*. 2003;160(5):1080–92.
 22. McGrath JJ, Burne TH, Féron F, MacKay-Sim A, Eyles DW. Developmental vitamin D deficiency and risk of schizophrenia: A 10-year update. *Schizophr Bull*. 2010;36(6):1073–8.
 23. Clarke M, Whitty P, Browne S, McTigue O, Kamali M, Gervin M, et al. Untreated illness and outcome of psychosis. *Br J Psychiatry*. 2006;189(SEP.):235–40.
 24. Lavretsky H. History of Schizophrenia as a Psychiatric Disorder. In: Mueser K, Jeste D, editors. *Clinical Handbook of Schizophrenia*. New York: Guilford Press; 2008. p. 3–12.
 25. DeBattista C. Antipsychotic agents & lithium. In: Katzung B, Trevor A, editors. *Basic & Clinical Pharmacology*. New York: McGraw-Hill Education; 2015. p. 491–502.
 26. Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: Overview and treatment options. *Pharm Ther*. 2014;39(9):638–45.
 27. Schizophrenia [Internet]. National Institution of Mental Health. 2009. [Diakses 2020 Okt 22]. Tersedia dari: <http://www.nimh.nih.gov/health/publications/schizophrenia-easy-to-read/nimh-schizophrenia-quadfold.pdf>
 28. Malaspina D, Owen MJ, Heckers S, Tandon R, Bustillo J, Schultz S, et al. Schizoaffective Disorder in the DSM-5. *Schizophr Res*. 2013;150(1):21–5.
 29. Wilson JE, Nian H, Heckers S. The schizoaffective disorder diagnosis: a conundrum in the clinical setting. *Eur Arch Psychiatry Clin Neurosci*. 2014 Feb;264(1):29–34.
 30. Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. A comparison of selected risk factors for unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia from a Danish population-based cohort. *J Clin Psychiatry*. 2007;68(11):1673–81.
 31. Azorin J-M, Kaladjian A, Fakra E. Aspects actuels du trouble schizo-affectif. *Encephale*. 2005;31(3):359–65.
 32. Kaplan HI, Sadock BJ. *Kaplan and Sadock's Synopsis of Psychiatry*:

- Behavioral Sciences/Clinical Psychiatry. 9th ed. Vol. 290, JAMA: The Journal of the American Medical Association. New York: Lippincott Williams & Wilkins; 2003.508–511 p.
33. Antonius D, Prudent V, Rebani Y, D'Angelo D, Ardekani BA, Malaspina D, et al. White matter integrity and lack of insight in schizophrenia and schizoaffective disorder. *Schizophr Res.* 2011 May;128(1–3):76–82.
 34. Radonić E, Radoš M, Kalember P, Bajš-Janović M, Folnegović-Šmalc V, Henigsberg N. Comparison of hippocampal volumes in schizophrenia, schizoaffective and bipolar disorder. *Coll Antropol.* 2011;35(SUPPL. 1):249–52.
 35. Smith MJ, Wang L, Cronenwett W, Mamah D, Barch DM, Csernansky JG. Thalamic morphology in schizophrenia and schizoaffective disorder. *J Psychiatr Res.* 2011 Mar;45(3):378–85.
 36. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. *Schizophr Bull.* 2009 Mar;35(2):383–402
 37. Kendler KS, Gardner CO, Prescott CA. Toward a comprehensive developmental model for major depression in men. *Am J Psychiatry.* 2006 Jan;163(1):115–24.
 38. Risperdal (risperidone) [Internet]. Titusville (NJ): Janssen Pharmaceutical Inc; 2007. [Diakses 2021 Jan 5]. Tersedia dari: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020272s082,020588s070,021444s056lbl.pdf
 39. National Center for Biotechnology Information. PubChem Compound Summary for CID 5073, Risperidone [Internet]. [Diakses 2021 Jan 15]. Tersedia dari: <https://pubchem.ncbi.nlm.nih.gov/compound/risperidone>.
 40. McNeil S, Gibbons J, Cogburn M. Risperidone [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. [Diakses 2021 Jan 18]. Tersedia dari: <https://www.ncbi.nlm.nih.gov/books/NBK459313/>
 41. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, et al. Risperidone versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev.* 2011;(1).
 42. Mitra S, Mahintamani T, Kavoor A, Nizamie S. Negative symptoms in schizophrenia. *Ind Psychiatry J.* 2016;25(2):135–44.
 43. Stępnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. *Molecules.* 2018;23(8):8–14.
 44. Saibi Y, Sato H, Tachiki H. Developing in vitro-in vivo correlation of risperidone immediate release tablet. *AAPS PharmSciTech.* 2012;13(3):890–5.
 45. Scott L, Dhillon S. Risperidone. *Pediatr Drugs.* 2007;9(5):343–54.
 46. Berecz R, Dorado R, De La Rubia A, Cáceres MC, Degrell I, Llerena A. The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions. *Curr Drug Targets.* 2004;5(6):573–9.
 47. Risperidone [Internet]. MIMS. [Diakses 2021 Jan 8]. Tersedia dari: <https://www.mims.com/indonesia/drug/info/risperidone>
 48. Lind CCK, Carchedi CLR, Staudenmeier LJJ, Diebold LPCJ. Atypical presentations of atypical antipsychotics. *Psychiatry (Edgmtont).* 2005;2(6):32–9.

49. Yarar C, Yakut A, Carman KB, Sahin S, Kocak O, Ozkan S, et al. Metoclopramide-Induced Acute Dystonia: Data From a Pediatric Emergency Unit. *Pediatr Emerg Care*. 2021;37(9):e528-e533.
50. Shin HW, Chung SJ. Drug-induced parkinsonism. *J Clin Neurol*. 2012;8(1):15–21.
51. Ward KM, Citrome L. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical Management. *Neurol Ther*. 2018;7(2):233–48.
52. Caroff S, Campbell E. Drug-Induced Extrapyrmidal Syndromes. *Psychiatr Clin North Am*. 2016 Jun 1;39.
53. Brasic J. Tardive Dyskinesia [Internet]. Medscape. 2018 [Diakses 2021 Feb 2]. Tersedia dari: <https://emedicine.medscape.com/article/1151826-overview>
54. Bohlega SA, Al-Foghom NB. Drug-induced Parkinson's disease. A clinical review. *Neurosciences (Riyadh)*. 2013;18(3):215–21.
55. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A, Assunção-Talbott S. Akathisia: An updated review focusing on second-generation antipsychotics. *J Clin Psychiatry*. 2009;70(5):627–43.
56. Salem H, Nagpal C, Pigott T, Teixeira AL. Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges. *Curr Neuropharmacol*. 2017;15(5):789–98.
57. Mehta SH, Morgan JC, Sethi KD. Drug-induced movement disorders. *Neurol Clin*. 2015;33(1):153–74.
58. Gershanik OS, Gómez Arévalo GJ. Typical and atypical neuroleptics. *Handb Clin Neurol*. 2011;100:579–99.
59. Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. Medication-induced tardive dyskinesia: A review and update. *Ochsner J*. 2017;17(2):162–74.
60. Thanvi B, Treadwell S. Drug induced parkinsonism: A common cause of parkinsonism in older people. *Postgrad Med J*. 2009;85(1004):322–6.
61. Bratti IM, Kane JM, Marder SR. Chronic restlessness with antipsychotics. *Am J Psychiatry*. 2007;164(11):1648–54.
62. Cloud LJ, Jinnah HA. Treatment strategies for dystonia. *Expert Opin Pharmacother*. 2010 Jan;11(1):5–15.
63. Inada T. [Drug-Induced Akathisia]. *Brain Nerve*. 2017 Dec;69(12):1417–24.
64. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. *Tremor Other Hyperkinet Mov (N Y)*. 2013 Jul 12;3:161-4138-1.
65. Pringsheim T, Doja A, Belanger S, Patten S, group CA for ME and S of A in C (CAMESA) guideline. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. *Paediatr Child Health*. 2011 Nov;16(9):590–8.
66. Hadisukanto G. Penentuan Validitas Skala Penilaian Gejala Ekstrapiramidal [Tesis]. Jakarta: Fakultas Kedokteran Universitas Indonesia; 1997.
67. Lestari ET. Perbedaan Skor PANSS, Indeks Massa Tubuh Pada Laki-Laki Dengan Skizofrenia yang Mendapat Terapi Olanzapin dan Risperidon Di

- Rumah Sakit Jiwa Prof. Dr. Muhammd Ildrem [Tesis]. Medan: Universitas Sumatera Utara; 2018. <https://repositori.usu.ac.id/handle/123456789/3834>
68. Saharuddin, Ikawati Z, Kristanto. Perbandingan Efektivitas Regimen Terapi Antipsikotik Pasien Schizophrenia di RSJ Dr. Ernaldi Bahar Palembang. *Maj Farm*. 2021;17(2):206–16.
 69. Agusmita. Perbedaan Kadar Magnesium Eritrosit Laki-laki Dengan Skizofrenia yang Mendapat Risperidon dan Haloperidol di Rumah Sakit Jiwa Prof. Dr. M. Ildrem Medan [Tesis]. Medan: Universitas Sumatera Utara; 2019. <https://repositori.usu.ac.id/handle/123456789/29736>
 70. Erlina, Soewadi, Pramono D. Determinan Terhadap Timbulnya Skizofrenia Pada Pasien Rawat Jalan Di Rumah Sakit Jiwa Prof. HB Saanin Padang Sumatera Barat. *Ber Kedokt Masy*. 2010;26(2):71–80.
 71. Dinar Alit M. Keefektifan Pemberian Clozapin Dibandingkan Risperidon Terhadap PANNS dan Kadar Inetroleukin-2 pada Pasien Skizofrenia Kronis Eksaserbasi Akut [Tesis]. Surakarta: Universitas Sebelas Maret; 2016. <https://eprints.uns.ac.id/30480/>
 72. Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender Differences in Schizophrenia and First-Episode Psychosis: A Comprehensive Literature Review. Henderson DC, editor. *Schizophr Res Treatment*. 2012;2012:916198.
 73. Park SG, Bennett ME, Couture SM, Blanchard JJ. Internalized stigma in schizophrenia: relations with dysfunctional attitudes, symptoms, and quality of life. *Psychiatry Res*. 2013 Jan;205(1–2):43–7.
 74. Trishna AR, Muhdi N. Clinical Manifestation Differences of Schizophrenia Patients Based on Gender. *J Psikiatri Surabaya*. 2020;9(1):14.
 75. Riecher-Rössler A, Kulkarni J. Estrogens and gonadal function in schizophrenia and related psychoses. *Curr Top Behav Neurosci*. 2011;8:155–71.
 76. Aryani F, Sari O. Gambaran Pola Penggunaan Antipsikotik pada Pasien Skizofrenia di Ruang Rawat Inap Rumah Sakit Jiwa. *J Manaj dan Pelayanan Farm*. 2016;6(1):35–40.
 77. Dickson H, Hedges E, Ma S, Cullen A, Maccabe J, Kempton M, et al. Academic achievement and schizophrenia: a systematic meta-analysis. *Psychol Med*. 2020 Jul 20;50:1–17.
 78. Mihaljevic-Peles A, Sagud M, Simunovic Filipic I, Grosic V, Pedisic I, Emsley R. Remission and employment status in schizophrenia and other psychoses: One-year prospective study in Croatian patients treated with risperidone long acting injection. *Psychiatr Danub*. 2016;28(3):263–72.
 79. Wulandari N. Pola Penggunaan Risperidon pada Pasien Skizofrenia di Unit Rawat Inap Rumah Sakit Jiwa Prof. Dr. Soerojo Magelang Periode September - Desember 2016 [Skripsi]. Yogyakarta: Universitas Gajah Mada; 2018. <http://etd.repository.ugm.ac.id/penelitian/detail/158550>
 80. Putri RA. Pengaruh Perbedaan Jenis Terapi Antipsikotik Terhadap Lama Rawat Inap Pasien Skizofrenia Fase Akut di Rumah Sakit Jiwa Daerah Sungai Bangkong Periode Januari - Desember 2014. *J Mhs Farm Fak Kedokt UNTAN*. 2015;
 81. Maylani RY, Fadraersada J, Ramadhan AM. Studi Pemberian Antipsikotik terhadap Beberapa Jenis Skizofrenia Di RSJD Atma Husada Mahakam

- Samarinda. In: Proceeding of Mulawarman Pharmaceuticals Conferences. 2018. p. 267–75.
82. Mohammad-Ali G, Faranak D. Extrapyramidal Side Effects of Risperidone in Iranian Schizophrenic Patients. *Res J Biol Sci*. 2008 Jan 1;
 83. Sykes DA, Moore H, Stott L, Holliday N, Javitch JA, Lane JR, et al. Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. *Nat Commu*. 2017;8(1):763.
 84. Thomson SR, Chogtu B, Bhattacharjee D, Agarwal S. Extrapyramidal Symptoms Probably Related to Risperidone Treatment: A Case Series. *Ann Neurosci*. 2017 Jul;24(3):155–63.
 85. Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, et al. Atypical antipsychotics and parkinsonism. *Arch Intern Med*. 2005 Sep;165(16):1882–8.
 86. Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. *Int Clin Psychopharmacol*. 2013 Mar;28(2):57–66.
 87. Bo Q-J, Li X-B, Wang Z-M, Li A-N, Ma X, Wang C-Y. Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study. *J Clin Psychopharmacol*. 2016 Apr;36(2):125–9.

